Prompt clinical response to secukinumab in patients with axial spondyloarthritis: Real life observational data from three italian referral centers

Stefano Gentileschi, Antonio Vitale, Donato Rigante, Giuseppe Lopalco, Giacomo Emmi, Ida Orlando, Gerardo Di Scala, Jurgen Sota, Claudia Fabiani, Bruno Frediani, Mauro Galeazzi, Giovanni Lapadula, Florenzo Iannone, Luca Cantarini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Clinical research is needed to identify patients with axial spondyloarthritis (axSpA) who are more likely to be responsive to interleukin (IL)-17 inhibition. Objectives: To evaluate short-term efficacy of secukinumab in the management of axSpA. Method: Twenty-one patients (7 males, 14 females) with axSpA were consecutively treated with secukinumab. Laboratory and clinical assessments were based on erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Data were recorded at baseline and at a 3 month follow-up visit. Results: The study was comprised of 21 patients. Both BASDAI and ASDAS-CRP showed a statistically significant reduction between the baseline and the 3 month visit (P < 0.0001 and P = 0.0005, respectively). During the laboratory assessment, ESR showed a significant decrease (P = 0.008) while CRP improvement did not reach statistical significance (P = 0.213). No statistical significance was observed between patients treated with secukinumab 150 mg vs. 300 mg in BASDAI (P = 0.99), ASDAS-CRP (P = 0.69), ESR (P = 0.54), and CRP (P = 0.56). No significant differences emerged between the BASDAI (P = 0.15), ASDAS-CRP (P = 0.09), and CRP (P = 0.15) rates in biologic-naïve patients and those previously failing tumor necrosis factor-α inhibition. Conversely, ESR decrease was significantly higher in the biologic-naïve subgroup (P = 0.01). No adverse events were reported. Conclusions: Secukinumab has proven remarkable short-term effectiveness, regardless of the biologic treatment line. A dosage of 150 mg proved to be appropriate in the clinical and laboratory management of axSpA.

Original languageEnglish
Pages (from-to)438-441
Number of pages4
JournalIsrael Medical Association Journal
Volume20
Issue number7
Publication statusPublished - Jul 1 2018

Keywords

  • Axial spondyloarthritis (axSpA)
  • Interleukin (IL)-17
  • Secukinumab
  • Seronegative arthritis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Prompt clinical response to secukinumab in patients with axial spondyloarthritis: Real life observational data from three italian referral centers'. Together they form a unique fingerprint.

Cite this